StockGuru Trade Alert: Guru Profile bioMETRX (BMRX) Up More than 19% Tuesday Morning
StockGuru Trade Alert: Guru Profile bioMETRX (BMRX) Up More than 19% Tuesday Morning Yesterday’s Close: $0.21 Today’s High So Far: $0.25
StockGuru Trade Alert: Guru Profile bioMETRX (BMRX) Up More than 19% Tuesday Morning Yesterday’s Close: $0.21 Today’s High So Far: $0.25
NextGen Bioscience, Inc. is a drug development biotechnology company focused on the identification, evaluation and acquisition of drug candidates for treatment and prevention of cancers and infectious diseases in human beings. “NextGen” leverages cutting-edge research collaborations to achieve breakthroughs in anti-cancer treatments, and then licenses these patented drug product candidates to Big Pharmaceutical companies. NextGen’s business model is to acquire promising new patented technologies in the fields of cancer and infectious disease, to add significant value to these by advancing them through toxicological assessment or Phase I clinical trials and then outlicensing the technology to a larger partner who has…
StockGuru Trade Alert: Profile Stock Lotus Pharmaceuticals (LTUS) Now Up More than 21% Since Friday Friday’s Close: $0.591 Today’s High So Far: $0.72 View the StockGuru Profile for LTUS: http://stockguru.com/profiles/ltus/
StockGuru Trade Alert: Guru Profile Financial Media (FNGP) Up More than 15% Today and More than 33% Since Last Week FNGP Has Moved from $0.15 to $0.20 in Less than a Week!
StockGuru Trade Alert: Profile Stock Phantom Fiber (PHFB) Up 24% on Volume More than 61 Times Ten-Day Average Ten-Day Average: 700 Today’s Volume: 43,117 View the StockGuru Profile for PHFB: http://stockguru.com/profiles/phfb/
NextGen Bioscience, Inc. (OTC: NXGB) NextGen Bioscience, Inc. (OTC: NXGB) - Monday’s shares closed down 2.44% to $0.40. 53,700 shares were traded. NextGen Bioscience, Inc. announced recently it is in collaboration negotiations with SymbioTec GmbH, a German company that has developed and patented an effective and commercially attractive cancer-fighting compound. The two companies have signed a Letter of Intent to come to a collaboration agreement. Konstantinos Kardiasmenos, CEO of NextGen, stated, “A strategic collaboration with SymbioTec would be a significant step in propelling both companies forward in our mutual goals to satisfy the lucrative and unmet demand for novel approaches…
LONDON, UNITED KINGDOM–Apr 8, 2008 — NextGen Bioscience, Inc., a biotechnology company that develops novel therapeutic proteins that disrupt the advance of life-threatening cancers, today announced it has acquired use, commercialisation and ownership rights of a patent application for the treatment of cancer from Oxon Life Science Inc. The patent application describes an improved method of identifying and purifying undifferentiated stem cells from solid breast carcinomas that are normally resistant to conventional therapies. The cancer stem cell is typically represented as a distinct population of cells within a tumour which may remain even if the rest of the tumour is…
StockGuru Trade Alert: Profile Stock Lotus Pharmaceuticals (LTUS) Up More than 15% Since Friday Friday’s Close: $0.591 Today’s High So Far: $0.68 View the StockGuru Profile for LTUS: http://stockguru.com/profiles/ltus/
StockGuru Trade Alert: Guru Profile Extreme Motorsports (EMOC) Up 40% on Volume More than 7 Times Ten-Day Average Ten-Day Average Volume: 6,026 Today’s Volume: 45,500
Intelligentias, Inc. (ITLI.OB) has become the newest member of the European Competitive Telecommunications Association (ECTA). The ECTA represents service providers and network equipment vendors to regulatory and governmental agencies, keeps a forum for telecommunications related business issues, and assists new companies entering the communications industry. Innocenzo Genna, ECTA Chairman, commented, "The European Union's adoption in 2006 of the Data Retention Directive places a considerable extra burden on telecommunications service providers and we are delighted that Intelligentias has joined our association to be able to bring their expertise into our community and potentially support ECTA members in this complex area." Intelligentias…